Ketoconazole/Tromethamine/Disodium Edta Dihydrate

Verify with FDA CVM →

36 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
36
Total Reports
1
Deaths Reported
280.0%
Death Rate

Active Ingredients

Ketoconazole/Tromethamine/Disodium Edta Dihydrate

Administration Routes

UnknownTopical

Species Affected

Dog 32
Cat 4

Most Affected Breeds

Pug 4
Domestic Shorthair 4
Shepherd Dog - German 3
Shih Tzu 3
Retriever - Labrador 3
Spaniel - Cocker American 2
Dog (unknown) 2
Crossbred Canine/dog 2
Spaniel - King Charles Cavalier 2
Bulldog 2

Most Reported Reactions

Lack of efficacy - NOS 11
Ataxia 8
Head tilt - ear disorder 6
Nystagmus 6
Vomiting 5
Ear discharge 5
Emesis (multiple) 5
Lethargy (see also Central nervous system depression in 'Neurological') 5
Erythema (for urticaria see Immune SOC) 3
Ear pruritus 3
Head shake - ear disorder 3
Anorexia 3

Outcome Breakdown

Outcome Unknown
20 (55.6%)
Recovered/Normal
15 (41.7%)
Euthanized
1 (2.8%)

Data Summary

Metric Value
Total adverse event reports 36
Reports involving death 1
Case-fatality rate (reported events) 280.0%
Distinct species in reports 2
Distinct breeds in reports 19
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Ketoconazole/Tromethamine/Disodium Edta Dihydrate Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 36 adverse event reports referencing Ketoconazole/Tromethamine/Disodium Edta Dihydrate, including 1 reports in which the animal died — a 280.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Ketoconazole/Tromethamine/Disodium Edta Dihydrate. Reported administration routes include Unknown, Topical. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Ketoconazole/Tromethamine/Disodium Edta Dihydrate reports are Dog (32 reports), Cat (4 reports), with Dog accounting for the largest share. Within those species, Pug (4), Domestic Shorthair (4), Shepherd Dog - German (3) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Ketoconazole/Tromethamine/Disodium Edta Dihydrate are Lack of efficacy - NOS (11), Ataxia (8), Head tilt - ear disorder (6), Nystagmus (6). Of the 36 reports with a coded outcome, Outcome Unknown is the leading category at 55.6%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Ketoconazole/Tromethamine/Disodium Edta Dihydrate.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial